Provided by Tiger Trade Technology Pte. Ltd.

Trevi Therapeutics, Inc.

11.58
-0.3500-2.93%
Pre-market: 11.47-0.1100-0.95%04:17 EDT
Volume:1.42M
Turnover:16.87M
Market Cap:1.48B
PE:-36.49
High:12.56
Open:12.16
Low:11.42
Close:11.93
52wk High:14.39
52wk Low:4.85
Shares:128.23M
Float Shares:97.09M
Volume Ratio:1.19
T/O Rate:1.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3173
EPS(LYR):-0.3173
ROE:-30.23%
ROA:-20.26%
PB:8.10
PE(LYR):-36.49

Loading ...

Trevi Therapeutics to host investor and analyst day, join healthcare conferences

Reuters
·
Yesterday

Analysts Conflicted on These Healthcare Names: Trevi Therapeutics (TRVI), Annexon Biosciences (ANNX) and Medtronic (MDT)

TIPRANKS
·
Mar 19

Stock Track | Trevi Therapeutics Plummets 5% Intraday After Morgan Stanley Cuts Target Price

Stock Track
·
Mar 19

Stock Track | Trevi Therapeutics Soars 7.15% in Pre-Market on Positive Analyst Coverage

Stock Track
·
Mar 18

Trevi Therapeutics Inc : Morgan Stanley Cuts Target Price to $18.00 From $19.00

THOMSON REUTERS
·
Mar 18

Trevi Therapeutics (TRVI) Receives a Buy from Stifel Nicolaus

TIPRANKS
·
Mar 18

Trevi Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 18

Earnings Flash (TRVI) Trevi Therapeutics Posts Q4 Loss $-0.06, vs. FactSet Est of Loss of $-0.10

MT Newswires Live
·
Mar 18

Trevi Therapeutics Q4 net loss narrows 27.13% to USD 8.32 million

Reuters
·
Mar 18

BRIEF-Trevi Therapeutics Q4 Net Income USD -8.316 Million

Reuters
·
Mar 18

Trevi Therapeutics Q4 Operating Expenses USD 10.22 Million

THOMSON REUTERS
·
Mar 18

Press Release: Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates

Dow Jones
·
Mar 18

Why Trevi Therapeutics (TRVI) Is Down 17.2% After Doubling Down On Parallel IPF Cough Trials - And What's Next

Simply Wall St.
·
Mar 15

Trevi Therapeutics to Host Conference Call on Q4 and Full-Year 2025 Results

Reuters
·
Mar 11

Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026

THOMSON REUTERS
·
Mar 11

Trevi Therapeutics completes End-of-Phase 2 meeting with FDA

TIPRANKS
·
Mar 09

Trevi Therapeutics plans two Phase 3 trials of nalbuphine ER for IPF-related chronic cough after FDA meeting

Reuters
·
Mar 09

Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting With the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough

THOMSON REUTERS
·
Mar 09

Trevi Therapeutics Inc - First Phase 3 Trial to Initiate in Q2 2026, Second in H2 2026

THOMSON REUTERS
·
Mar 09

Trevi Therapeutics to Join Leerink Partners Global Healthcare Conference Fireside Chat

Reuters
·
Mar 02